https://cadd522inhibitor.com/f....amilial-risks-in-bet
From an overall total of 214 readily available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genetics, respectively. Making use of a Sanger-like cut-off, the entire prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations had been 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Just three (1.7%) topics had INSTI TDR (R263K, E138K and G163R), while minority variations
Like
Comment
Share
